C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/09 (2006.01) A61K 31/70 (2006.01) A61K 39/00 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C07K 14/705 (2006.01) C07K 16/28 (2006.01) C12N 15/11 (2006.01) C12Q 1/00 (2006.01) G01N 33/531 (2006.01) G01N 33/574 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2322903
The invention relates to overcoming anti-cancer therapy resistance in melanoma by regulation of the expression of tyrosinase related protein 2 (TYRP2). Treatment of melanoma with anti-cancer therapy may be negatively impacted by anti-cancer resistance of melanoma cells. Altering expression of TYRP2 in melanoma cells can enhance efficacy of anti-cancer therapies, such as chemotherapy and radiotherapy. The use of a TYRP2 reducer, ase well as methods for treatment of melanoma are disclosed. Further, methods for diagnosis of anti-cancer therapy resistance, and methods for evaluating candidate anti-cancer therapies for melanoma. Down-regulation of TYRP2 expression or activity can be accomplished using a genetic therapy such as antisense therapy, or by using small molecules which regulate TYRP2.
Ben-David Yaacov
Kerbel Robert S.
Pak Brian J.
Ben-David Yaacov
Borden Ladner Gervais Llp
Kerbel Robert S.
Pak Brian J.
Sunnybrook Health Sciences Centre
LandOfFree
Treatment, diagnosis and evaluation of anti-cancer therapy... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment, diagnosis and evaluation of anti-cancer therapy..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment, diagnosis and evaluation of anti-cancer therapy... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2023543